pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

Astellas Pharma Inc

updated 21d ago

Astellas Pharma Inc. is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd. .

Website ↗
community read0 votes

🐶 often sniffed alongside

top 5
  • companyAstellas Pharma US Inc8 co-mentions · 2 sources
  • drugLP-3108 co-mentions · 2 sources
  • tagRecall4 co-mentions · 2 sources
  • drug386574 co-mentions · 2 sources
  • drugTACROLIMUS4 co-mentions · 2 sources
pipeline
8
marketed
1
phase 3
0
catalysts ytd
1
approvals ytd
1
recalls ytd
0

Pipeline(8)

pipeline depth8 products
Phase 2: 4Marketed: 1Unknown: 3
4Phase 21Marketed3Unknown
Marketed
enfortumab vedotin
Muscle Invasive Bladder Cancer (MIBC)
Nectin-4Tubulin
Phase 2
ASP-2957
X-Linked Myotubular Myopathy (XLMTM or MTM)
Phase 2
ASP-7316
Juvenile Macular Degeneration (Stargardt Disease)
Phase 2
zocaglusagene nuzaparvovec
Pompe Disease
Phase 2
zolbetuximab
Metastatic Adenocarcinoma of The Pancreas
Claudin-18
drug
IZERVAY
drug
PADCEV
drug
XTANDI

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase1A Study of ASP3082 in Adults With Advanced Solid Tumorsrecruitingn=681
  • phase2A Study of ASP2246 for People Who Have Movement Problems Caused by Brain Injury After a Strokerecruitingn=84
  • phase4A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degenerationactive not recruitingn=17
  • phase1A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumorsrecruitingn=364
  • phase3A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutationactive not recruitingn=276
  • phase3A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through Menopausecompletedn=277
  • —Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritisrecruitingn=3,000
  • phase1A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumorsactive not recruitingn=175
more trials →
🐶 Hiring Signal
No open roles indexed yet — view Astellas Pharma Inc jobs →

News

  • Kolon TissueGene cuts 37 US staffers after Phase 3 fail
    Follow along as BioSpace tracks job cuts and restructuring initiatives.
    biospace · 1d ago
  • PTC takes a chance on Sangamo’s Fabry disease gene therapy
    Wall Street analysts view the deal as a risky, high-reward bet on a treatment that’s nearing a possible regulatory approval and could be superior to existing medications.
    biopharma_dive · 7d ago
  • Silence cashes in on ‘differentiated’ data; UK reaffirms support for childhood vaccines
    Some analysts believe Silence’s polycythemia vera drug could be superior to a closely watched Takeda medicine. Elsewhere, the FDA spurned a radiopharmaceutical and AbCellera shares climbed to level…
    biopharma_dive · 8d ago
  • Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch
    Some analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.
    biopharma_dive · 15d ago
  • AI data becomes sticking point in biopharma dealmaking
    As drug hunting gets more complex, where and how data is generated in partnerships between Big Pharmas and AI biotechs is becoming a headache for dealmakers.
    biospace · 29d ago
  • Agenus surges on study pivot; Apnimed lines up an IPO
    Agenus is financially abandoning an ongoing study in late-line colorectal cancer. Elsewhere, an ebola vaccine began human testing and an important Bristol Myers medicine got an FDA decision date.
    biopharma_dive · 1mo ago
  • Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers
    Hundreds of executives and investors are pushing for Rick Pazdur to be the next FDA commissioner. Elsewhere, Takeda detailed its latest restructuring and Alumis is discarding a once-highly touted i…
    biopharma_dive · 3mo ago
  • Fierce Biotech Layoff Tracker 2026: Kolon cuts workforce after ph. 3 fail; Sanofi sheds 229 staffers
    As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.
    fiercebiotech · 8mo ago
view all news mentions →
identifiers
source
globaldata
top tags
Oncology2Ophthalmology1
mentioned in
8news items
entity-linker matched
Data sources
openFDA
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?